Manufacturing News of Note—WuXi Biologics resumes China production; Samsung Biologics expands; Catalent, Zumutor sign deal

A closeup of a stock market ticker
(Pixabay)

> China’s WuXi Biologics resumed production this week at its three sites but says it is taking precautions to protect its employees and products in the face of the COVID-19 outbreak. Release 

> Korean CDMO Samsung Biologics announced it will expand its manufacturing this year after reporting a 30.9% growth in sales and 64.6% growth in operating profit. Release  

> Chinese API maker WuXi STA has opened a 30,000-square-foot large-scale oligonucleotide manufacturing facility in Changzhou, China, as more drugs using the active ingredient are approved. Release

> Bioprinter CELLINK and AstraZeneca have extended by 12 months their collaboration on 3D-bioprinted tissues. Release 

> CDMO Catalent has signed an agreement with Zumutor Biologics to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors. Release

> Amgen says its next-generation biologics manufacturing, which will have a smaller footprint and lower use of energy, will be key to achieving its next environmental goals. Story

> Nanjing King-Friend Biochemical Pharmaceutica, which has a facility in, Nanjing, China, had a new generics injectable line approved by the FDA. Release

> Pharmaceutical development company Velesco Pharma has started operations at a new clinical manufacturing facility in Wixom, Michigan, that will triple its manufacturing capacity. Release (PDF)

> Helsinki-based Nanoform has opened a subsidiary in the U.S. even as it seeks GMP approval at a Finland site to serve the U.S. market with its nanonization technology. Release

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

The end is near for a Novartis site in the U.K., and the 400 workers there. The Swiss drugmaker will close the site this year unless a buyer is found.